Milestone Pharmaceuticals (MIST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright maintained a Buy rating on the stock and has a $25.00 price target.
Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Milestone Pharmaceuticals. Despite a delay in the approval timeline for their drug CARDAMYST, caused by Chemistry, Manufacturing, and Controls (CMC) issues, the clinical efficacy and safety of the drug remain uncompromised. This supports the integrity of the clinical data, which aligns well with FDA expectations, reinforcing confidence in the product’s potential.
Furthermore, the PSVT market is notably underserved, with a significant patient population in the U.S. This presents a substantial opportunity for CARDAMYST to become a first-line treatment for acute PSVT episodes, a notion supported by key opinion leaders and market research. Milestone’s robust cash position, expected to last into mid-2026, and their strategic efforts to build a specialized salesforce, further underpin the potential for a successful launch once approved. The valuation, based on a discounted cash flow methodology, estimates a firm value of approximately $2 billion, supporting a price target of $25.
In another report released on March 14, TD Cowen also maintained a Buy rating on the stock with a $9.00 price target.